Relevant studies, published up to June 2021, were searched through PubMed/Medline, Scopus, ISI Web of Science, EMBASE and Google Scholar. The mean differences and standard deviations were pooled using a random-effects model. The studies\' quality was evaluated using the Cochrane Risk of Bias Tool.
Out of 80 citations, 5 trials that enrolled 549 participants were included. Berberis aristate and Silybum marianum resulted in no statistically significant change in ALT (weighted mean differences (WMD): -0.39 mg/dl; 95% CI: -1.67 to 0.89, P = 0.55), and AST (WMD: -0.44 mg/dl; 95% CI: -2.02 to 1.14, P = 0.58).
We did not find any significant reduction in liver enzymes following BBR-silymarin consumption in adults. Further clinical trials with high quality according to the challenges mentioned seem to be helpful to use BBR-silymarin as a supplement for improving liver function.
相关研究,截至2021年6月发布,通过PubMed/Medline搜索,Scopus,ISIWebofScience,EMBASE和谷歌学者。使用随机效应模型汇集平均值差异和标准偏差。使用Cochrane偏差风险工具评估研究质量。
在80篇引文中,纳入549名参与者的5项试验。小檗碱和水飞蓟菌导致ALT无统计学意义的变化(加权平均差异(WMD):-0.39mg/dl;95%CI:-1.67至0.89,P=0.55),和AST(WMD:-0.44mg/dl;95%CI:-2.02至1.14,P=0.58)。
我们没有发现成人食用BBR-水飞蓟素后肝酶有任何显著降低。根据提到的挑战,高质量的进一步临床试验似乎有助于使用BBR-水飞蓟素作为改善肝功能的补充。